Cybin(CYBN)

Search documents
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
Businesswire· 2024-03-13 10:00
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that the FDA has granted BTD to CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of MDD. If approved by the FDA, CYB003 would be the first known adjunctive psychedelic-bas ...
Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003
Businesswire· 2024-03-13 02:37
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that it will host a conference call and webcast at 8:30 a.m. ET on Wednesday, March 13, 2024. The Company will provide a program update on CYB003, its proprietary deuterated psilocybin analog in development for the adj ...
Cybin to Present at the TD Cowen 44th Annual Health Care Conference
Businesswire· 2024-02-27 12:30
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the TD Cowen 44th Annual Health Care Conference, taking place March 4-6, 2024 in Boston, MA. Mr. Drysdale’s presentation will be webcast live on Mon ...
Cybin Reports Third Quarter Financial Results and Recent Business Highlights
Businesswire· 2024-02-14 12:45
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, today reported unaudited financial results for its third quarter ended December 31, 2023, and recent business highlights. “ During the past three months, we have continued to make exciting progress with positive topline data from our CYB003 ...
Cybin(CYBN) - 2023 Q4 - Annual Report
2024-02-13 16:00
Cybin Inc. Management's Discussion and Analysis of Financial Condition and Operating Performance For the three and nine months ended December 31, 2023 Date: February 13, 2024 CYBIN INC. Management's Discussion and Analysis This Management's Discussion and Analysis ("MD&A") has been prepared by management of Cybin Inc. ("Cybin" or the "Company") and should be read in conjunction with Cybin's interim condensed consolidated financial statements and notes for the three and nine months ended December 31, 2023 (t ...
Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program
Businesswire· 2024-02-07 12:30
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that the Japan Patent (“JP”) Office has granted JP patents 2023-500532 and 2023-533436. The patents, which are expected to provide exclusivity until at least 2040 and 2041, respectively, include protection for a synthe ...
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition
Prnewswire· 2024-01-24 14:00
FN Media Group News Commentary PALM BEACH, Fla., Jan. 24, 2024 /PRNewswire/ -- The coming years could see a massive shift in the U.S. government's approach to regulating hallucinogenic drugs. Several biopharma companies are developing psychedelics-based treatments for various mental health conditions like Generalized Anxiety Disorder (GAD). GAD is a prevalent mental health condition characterized by excessive and persistent worry, often extending beyond specific triggers. Individuals with GAD experience he ...
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder
Businesswire· 2024-01-23 12:30
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared its investigational new drug (“IND”) application for CYB004, its proprietary deuterated dimethyltryptamine (“DMT”) molecule in development for the treatment of Ge ...
Cybin(CYBN) - 2023 Q3 - Quarterly Report
2023-11-14 16:00
Cybin Inc. Management's Discussion and Analysis of Financial Condition and Operating Performance For the three and six months ended September 30, 2023 Date: November 14, 2023 CYBIN INC. Management's Discussion and Analysis This Management's Discussion and Analysis ("MD&A") has been prepared by management of Cybin Inc. ("Cybin" or the "Company") and should be read in conjunction with Cybin's interim condensed consolidated financial statements and notes for the three and six months ended September 30, 2023 (t ...
Cybin(CYBN) - 2023 Q2 - Quarterly Report
2023-11-12 16:00
November 10, 2023 Cybin Inc. 100 King Street West, Suite 5600 Toronto, Ontario M5X 1C9 Each Unit will consist of one Common Share (as hereinafter defined) (each, a "Unit Share" and collectively, the "Unit Shares") and one Common Share purchase warrant (each, a "Warrant" and collectively, the "Warrants"). Each whole Warrant will entitle the holder thereof to purchase one additional Common Share (each, a "Warrant Share" and collectively, the "Warrant Shares"), subject to adjustment in certain circumstances, a ...